Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP3A4*22 genotype-guided dose reduction of CYP3A4-metabolized tyrosine kinase inhibitors in cancer patients
NL-OMON45864Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2019
- Countries
- 1
01
Overview
Phase 4, open-label trial in cancer and Neoplasm (2 arms), sponsored by Erasmus MC. Started Mar 2019; status: active, not recruiting.
02
Conditions
cancerNeoplasm
Beyond the preview
Go deeper on NL-OMON45864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45864.